

Appl. No. 10/056,788  
Amdt. dated September 12, 2005  
Reply to Office Action of March 10, 2005

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1. (Currently amended) A method of expressing Factor IX in a mammal, comprising:  
providing a preparation of recombinant adeno-associated virus (rAAV) virions, said preparation lacking the components necessary to form replication competent adenovirus, said rAAV virions comprising an AAV-6 capsid and a heterologous nucleic acid encoding Factor IX, wherein said heterologous nucleic acid is operably linked to expression control elements; and  
administering said preparation by intramuscular injection to at least one muscle cell of a mammal.
2. (Original) The method of claim 1, wherein said Factor IX is human Factor IX.
3. (Currently amended) A method of delivering a heterologous nucleic acid to at least one muscle cell in a mammalian subject, comprising:  
(a) providing a preparation of recombinant adeno-associated virus (rAAV) virions, said preparation lacking the components necessary to form replication competent adenovirus, said rAAV virions comprising an AAV-6 capsid and a heterologous nucleic acid, wherein said heterologous nucleic acid is operably linked to expression control elements; and  
(b) administering said preparation by intramuscular injection to said muscle cell.
4. (Previously presented) The method of claim 3, wherein said heterologous nucleic acid is a gene encoding a protein.
5. (Withdrawn) The method of claim 3, wherein said heterologous nucleic acid is an antisense RNA.

Appl. No. 10/056,788  
Amdt. dated September 12, 2005  
Reply to Office Action of March 10, 2005

6. (Withdrawn) The method of claim 3, wherein said heterologous nucleic acid is a ribozyme.

7. (Original) The method of claim 4, wherein said protein is a secreted protein.

8. (Original) The method of claim 7, wherein said secreted protein is a blood coagulation factor.

9. (Original) The method of claim 8, wherein said blood coagulation factor is human factor IX.

10. (Cancelled)

11. (Previously presented) The method of claim 3, wherein said muscle cell is a skeletal muscle cell.

12. (Currently amended) A method of delivering a heterologous nucleic acid to at least one muscle cell in a mammalian subject, comprising:

(a) providing a preparation of recombinant adeno-associated virus (rAAV) virions, said preparation lacking the components necessary to form replication competent adenovirus, said rAAV virions comprising an AAV-6 capsid and a heterologous nucleic acid, wherein said heterologous nucleic acid is operably linked to expression control elements; and

(b) administering said preparation to said muscle cell ~~The method of claim 3, wherein said administering of said preparation is by way of administration to a vascular conduit of said mammalian subject.~~

13. (Previously presented) The method of claim 12, wherein said vascular conduit is a vein.

Appl. No. 10/056,788  
Amdt. dated September 12, 2005  
Reply to Office Action of March 10, 2005

14. (Previously presented) The method of claim 12, wherein said vascular conduit is an artery.

15 - 21. (Cancelled).